Health · Bagsværd, Denmark · October 20, 2026

Novo's CagriSema shows 25% weight loss in women in late-stage analysis

Reported by 1 outlet · first reported Oct 20, 12:11 PM ET

Novo Nordisk released a late-stage analysis showing its experimental CagriSema injection produced 25% weight loss in women. The company said it could improve on results from its existing obesity drug Wegovy.

Why it matters

More effective obesity treatments could reach millions of patients and reshape a fast-growing drug market.

Background

Novo Nordisk makes Wegovy and Ozempic, GLP-1 drugs that transformed obesity treatment. It competes closely with Eli Lilly.

Sources

• CNBC ↗Oct 20, 12:11 PM ET

This summary was written automatically from the reporting linked above; follow the sources for the full story. How One Turn works.

See it on the globe →All of Oct 20's stories